Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.
Jean L. Grem(National Cancer Institute), R. Wittes(National Institutes of Health), Richard S. Ungerleider(Unknown), Brian Leyland‐Jones(Avera Health), Daniel F. Hoth(National Institutes of Health), Susan A. King(National Institutes of Health)
Cited by 16
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
|Biochemistry|1981|375
Representation of older patients in cancer treatment trials
|Cancer|1994|349
Representation of African-Americans, Hispanics, and Whites in National Cancer Institute Cancer Treatment Trials
|JNCI Journal of the National Cancer Institute|1996|275